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Objectives: To evaluate bone healing following implantation of a statin with two 
different carriers in rabbit nasal bone using histological and immunohistochemical 
methods.  
Materials and methods: Twenty adult male Japanese white rabbits (age: 12–16 weeks, 
weight: 2.5–3.0 kg) were used in this study.  Five bone circular defects (5 mm in 
diameter) per rabbit were created in the nasal bone while preserving the nasal 
membrane. In the experimental groups, 2.5 mg/ml simvastatin dissolved in 0.2 ml water 
with hydrogel was implanted in one group, 2.5 mg/ml simvastatin dissolved in 0.2 ml 
water with an atelocollagen sponge (ACS) in the second group with, only the hydrogel 
in the third group and only an ACS in the fourth group.  No material was implanted in 
the control group.  4 animals were killed in each period, at 1-, 2-, 4-, 8- and 12 weeks 
postoperatively.  The parts that had been operated on were removed and prepared for 
histological assessment.  The expression of BMP-2 and the bone ration was evaluated 
using histological and immunohistochemical methods. 
Results: No significant differences were observed between the simvastatin with 
hydrogel group and the simvastatin with ACS group at 1, 2, 4, 8 and 12 weeks 
postoperatively regarding expression of BMP-2, although the number of cells that 
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stained positive for BMP-2 in both of the implanted groups increased significantly at 2 
and 4 weeks postoperatively in comparison with the control group (P<0.0001). For new 
bone area ratio, there were no significant differences between the simvastatin with 
hydrogel groups and the simvastatin with ACS group after 2, 4, 8 and 12 weeks, although 
these groups showed higher value than control group (P<0.0001). 
Conclusion: This study suggests that both the simvastatin with hydrogel and 
simvastatin with ACS implants showed similar BMP-2 expression and new bone 








Statins are specific, competitive inhibitors of 3-hydroxy-2-methyl-glutaryl 
coenzyme A (HMG CoA) reductase, and include naturally occurring lovastatin, 
chemically modified simvastatin and pravastatin and the synthetically derived 
atorvastatin, fluvastatin, and cerivastatin (Henwood & Heel 1988; Kishida et al. 1991; 
Todd & Goa 1990). All of these agents are widely used to lower cholesterol, and they 
provide an important and effective approach towards the treatment of hyperlipidemia 
and arteriosclerosis (Hunninghake 1998). However, statins also appear to modulate 
bone formation, inflammation, and angiogenesis.  The suggestion that statins can 
increase bone formation has provided an exciting new direction for research as well as 
providing a greater understanding of the biological importance of cholesterol synthetic 
pathways. Simvastatin, mavastatin, and lovastatin have been shown to stimulate bone 
formation (Mundy et al. 1999).  
Statins (Simvastatin in particular) can promote osteoblast viability and 
differentiation via membrane-bound Rss/Smad/Erk/BMP-2 pathway (Chen et al. 2010). 
Bone morphogenetic proteins (BMPs) are active bone-inducing factors that act on 
immature mesenchymal cells, including osteoblasts, resulting in osteogenesis (Wozeny 
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et al. 1988). The evaluation of the BMP-2 expression is most adequate way to 
investigate ability of bone healing and regeneration. Si et al (1997) found that the 
BMP-2 signal was greatest at the stage of intramembranous formation of bone and early 
chondrogenesis, suggested that BMP-2 mediates the differentiation of meshenchymal 
cells into osteoblasts and chondroblasts. BMP-2 expression and new bone formation 
have been reported in our previous studies (Marukawa etal. 2005, Alam et al. 2007, 
Alam et al. 2009, Marukawa etal. 2010). Therefore, BMP-2 expression was chosen in 
this study. To develop more effective bone graft materials with enhanced osteogenic 
properties, alloplastic materials are combined with osteoinductive substances such as 
BMPs and statin (Yamomoto et al. 2003; Tanigo et al. 2010). Numerous carriers were 
shown to be compatible with the osteoinductive activity (Uludag 1998). Among them, 
collagen-based carriers are being used in clinical settings. Wong et al. (2005) 
demonstrated that purified fibrillar collagen is a good delivery vehicle for statins and is 
osteoinductive when grafted into skull defects.   
Medgel® (gelatin hydrogel) is a gelatin-based hydrogel for the sustained 
release of the drug. It was developed on the basis of the research results of Tabata et al. 
(Tabata et al. 1994; Yamamoto et al. 2000; Ozeki et al. 2001; Yamamoto et al. 2003; 
Tanigo et al. 2010). However, it has not yet been approved for clinical use in humans. 
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Gelatin is a denatured form of collagen, which is the most abundant component of 
extracellular matrix in body tissue. The material itself and the product when degraded 
are both biocompatible. The advantages of gelatin are the ease of chemical modification 
and the commercial availability of materials with different physicochemical properties. 
Tabata et al. have prepared hydrogels with different biodegradabilities from gelatin or 
the derivatives and succeeded in augmenting the therapeutic activities of water-soluble 
drugs, such as growth factors, chemokine, plasmid DNA, anti-tumor drug, and siRNA 
(Fukunaka et al. 2002; Konishi et al. 2003; Matsumoto et al. 2006; Nakamura et al. 
2008; Kimura & Tabata 2010).  Thus, since this material could be expected to 
regenerate new bone, this was selected in this study.  
Teruplug® (ACS) was developed as a form of sponge by combining fibrillar 
atelo-collagen with gelatin, to minimize antigenicity, which is cross-linked by heat 
treatment for biocompatibility (Koide et al. 1993). It features a sponge block design and 
is shaped for easy insertion in the extraction wound. It consists of between 85 and 95% 
of collagen type I and between 5 to 15% of collagen type III. The raw material for the 
collagen is derived from bovine skin. This material can be used for humans, and it is 
inserted in the extraction wound where alveolar bone is exposed. It protects wounds and 
promotes the formation of granulation. This material has adequate residual character of 
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the volume, so that it can have space maintain mechanical properties and surrounding 
cell can infiltrate (Matsui 2008). It is suggested that this can induce injury healing 
rapidly and new bone formation. We have used this material in both clinical and 
experimental studies, and satisfactory results have been obtained. Therefore, this 
material was selected in this study for use in a clinic setting. 
The purpose of this study was to evaluate bone healing following implantation 
of a statin with two different carriers (atelocollagen sponge (ACS) and hydrogel) in 
rabbit nasal bone using histological and immunohistochemical methods.  
 
Materials and Methods 
 
The experimental protocol was approved by the Institutional Committee for 
Animal Care, Kanazawa University. 
 
Experimental animals 
Twenty white, male Japanese rabbits (12-16 weeks, 2.5-3.0 kg) were used in 




 The whole procedure was performed under sterile conditions. First, the animals 
were anesthetized with sodium pentobarbital (25 mg/kg), injected into the lateral ear vein. 
Then the hair on the nasal bone was shaved. Next, 1.8 ml of 2% lidocaine containing 
1:80,000 epinephrine was administered into the operating site. Both the nasal bone and 
nasoincisinal suture line were exposed via a perpendicular incision. With the use of a 
fissure bur, four nasal bone windows were outlined. A surgical defect (5mm in diameter) 
was made with a fissure bur using continuous saline irrigation. Small leads of mechanical 
pencil were implanted beside the defects as markers to distinguish the defect area from 
periphery bone at later period. Great care was taken to avoid injuring the nasal membrane. 
Five bone defects per rabbit were created in the nasal bone while preserving the nasal 
membrane (Fig. 1). In the experimental groups, one group was implanted with 2.5 
mg/ml simvastatin (Wako Junyaku Inc., Osaka, Japan) dissolved in 0.2 ml water with 
hydrogel (Medgel®, Medgel Co. Kyoto, Japan). Gelatin hydrogel incorporating 
simvastatin was dropped onto freeze-dried Medgel® and left overnight at 4 ºC. The 
second group was implanted with 2.5 mg/ml simvastatin dissolved in 0.2 ml water with 
an atelocollagen sponge (ACS) (Teruplug®, Terumo Co. Tokyo, Japan), in the third 
group only the hydrogel was implanted and the forth group only ACS was implanted.  
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No material was implanted in the control group. In short, an animal included 5 defects 
(groups). 4 animals were sacrificed in each period, at 1-, 2-, 4-, 8- and 12 weeks 
postoperative.  Bone defect in this study is defined as a critical defect in size. This size 




 The specimens were fixed with 10% buffered formaldehyde overnight at 4°C, 
and demineralized with 14% EDTA for 4 weeks. The specimens were dehydrated with a 
graded ethanol series, cleared with xylene and embedded in paraffin. Five-mm multiple 
sections were cut parallel to coronal plane of the head at the center region in each 
defects and mounted on gelatin-coated glass slides. Firstly, the prepared sections were 
stained with hematoxyline and eosin (HE). The new bone area ratio was measured with 
an image software (Scion image, Scion corporation ML, USA) (Fig.2). The measurement 
was performed 5 times by an author (A.M.) to confirm the reproducibility of the scores 
and mean value was used as results. 
Then, they were treated successively with 0.3% tween 20 (Tokyo chemical industry 
Co.LTD, Tokyo, Japan) in phosphate buffered saline (PBS) for one hour for cell 
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permeabilization, and then with 0.3% hydrogen peroxide in methanol for 10 min to 
inhibit intrinsic peroxides activity. They were then incubated overnight at room 
temperature with antibody BMP-2 (Wako, Osaka, Japan) at a 1: 100 dilution in PBS. 
After washing with PBS, the sites of the immunoreactions were visualized by incubating 
the sections successively with biotinylated anti rabbit IgG antibody at a 1: 200 dilution for 
1hr, horseradish peroxides –conjugated streptavidin (Dako Japan, Tokyo, Japan) at a 1: 
300 dilution for 1 hr, and 0.01% diaminobenzidine tetrahydrochloride in the presence of 
0.02% hydrogen peroxide in 50 mM Tris-HCL, pH 7.5 for 10 min.. The sections 
counterstained with hematoxylin were observed under on Olympus BX 50 microscope 
(Olympus; Tokyo, Japan). The sections were then dehydrated in alcohol and mounted for 
light microscopy to count the number of positively stained active cells in the regeneration 
site. The observation area was determined at the center region of the bone defect area 
(material implanted area) (Fig.2). The number of BMP-2 stained cells per voluntary 1000 
cells in this area was counted manually using a high magnification photomicrograph 
(×100). The measurements were performed 5 times by an author (A.M.) to confirm the 
reproducibility of the scores, mean value was used as results. 
 
Statistical Analysis  
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Data of all the implanted materials were statistically analyzed with Stat View 4.5 
(ABACUS Concepts, Inc., Berkeley, CA, USA) and Dr. SPSSII (SPSS Japan Inc., 
Tokyo, Japan). Time-dependent changes were examined by analysis of variance 
(repeated measure ANOVA), after test for assumption of normality in each group were 
made. Differences between groups were analyzed by non-paired comparison using 
Scheffe’s F test. Differences were considered significant at P< 0.05. 
 
Results 
Healing progressed uneventfully in all the animals and no postoperative 
complications were noted during the 12 week observation period. After resting for 3-6 
days postoperatively, the animals could move and leap without any notable pain or 
limitation. 
 
Histological examination  
 
Simvastatin with hydrogel 
The hydrogel structure was absorbed remarkably, and fibrous tissue including 
osteoblasts was partially found in the region 1 week later. Fibrous tissue was observed 
 12
after 2 and 4 weeks and was still present after 8 and 12 weeks. Hydrogel could be 
observed after 4 weeks, but it could not be identified after 12 weeks. New bone 
formation was observed partially after 2 weeks (bone area ratio: mean 14.8%) and it 
continued to increase until 12 weeks postoperative (Figs. 3,4,5,7,8 and9).   
 
Simvastatin with ACS 
   ACS structure was absorbed remarkably, and fibrous tissue including osteoblast was 
partially found in the region 1 week later. Fibrous tissue was observed after 2 and 4 
weeks and was still present after 8 and 12 weeks. ACS could be observed after 4 weeks, 
but it could not be identified after 12 weeks. New bone formation was observed 
partially after 2 weeks (bone area ratio: 14%) and it continued to increase until 12 
weeks postoperative (Figs. 3,4,5,7,8 and9). 
 
Hydrogel alone 
   Hydrogel was absorbed remarkably after 1 and 2 weeks, but formation of fibrous 
tissue including osteoblast was slower than simvastatin with two carriers. The remaining 
hydrogel structure existed partially until 8 weeks postoperative. Fibrous tissue could be 
observed after 4, 8 and 12 weeks. New bone was partially observed after 2 weeks (bone 
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area ratio: mean 0.5%), and it increased after more than 4 weeks (Figs. 3,4,5,7,8 and9). 
 
ACS alone 
  ACS was absorbed remarkably after 1 and 2 weeks, but formation of fibrous tissue 
including osteoblast was slower than simvastatin with two carriers. The remaining of 
the ACS structure existed partially until 8 weeks postoperative. Fibrous tissue could be 
observed after 4, 8 and 12 weeks. New bone was partially observed after 2 weeks 
(bone area ratio: mean 0.8%), and it increased after more than 4 weeks (Figs. 3,4,5,7,8 
and9). 
 
Control (no material) 
   The blood clot was still present after 1 week. Fibrous tissue could be observed after 
2 weeks, and it filled in the defect after 4 weeks. New bone could be found slightly after 
4 weeks (bone area ratio: mean 0.8%), and it increased after more than 8 weeks (Figs. 
3,4,5,7,8 and9).  
  
Epithelial tissue except for nasal membrane and muscular tissue were not found in all 




Number of BMP-2 stained cells 
For BMP-2 antibody, these time-course changes showed statistically significant 
differences by ANOVA (between subjects; F=60.666, df=4, P<0.0001; within subjects; 
F=14.098, df=16, P<0.0001).  After 2 weeks, the simvastatin with hydrogel group and 
the simvastatin with ACS group showed maximum values for the number of BMP-2 
stained cells (Fig.5). However, there were no significant differences between both 
groups after 2, 4, 8 and 12 weeks. Similarly, there were no significant differences 
between the hydrogel alone group and the ACS alone group after 2, 4, 8 and 12 weeks. 
After 1 week, the simvastatin with ACS group was significantly larger than the control 
group (P=0.0150), however there were no significant differences between other groups. 
After 2 weeks, the simvastatin with hydrogel group showed a significantly higher value 
than the hydrogel alone group (P=0.0011) and the control group (P=0.0002). Similarly, 
the simvastatin with ACS group also showed a significantly higher value than the ACS 
alone group (P=0.0029) and the control group (P=0.0008). However, there were no 
significant differences between the hydrogel alone group and the control group, and 
between the ACS alone group and the control group. After 4 weeks, simvastatin with 
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ACS group significantly showed higher value than the control group (P=0.0199). 
However, there were no significant differences between the other groups. After 8 weeks, 
there were no significant differences in all groups. After 12 weeks, the control group 
showed a higher value than the other groups (vs. the hydrogel alone group; P=0.0160, vs. 
the ACS alone group; P=0.089, vs. the simvastatin with hydrogel group; P=0.0248, vs. 
the simvastatin with ACS group; P=0.0439). However, there were no significant 
differences between the groups regarding implanted materials (Fig. 10, Table 1 and 3). 
 
Bone area ratio 
For new bone area ratio, these time-course changes showed statistically significant 
differences by ANOVA (between subjects; F=12792.687, df=4, P<0.0001; within 
subjects; F=247.645, df=16, P<0.0001).  There were no significant differences 
between the simvastatin with hydrogel groups and the simvastatin with ACS group after 
2, 4, 8 and 12 weeks. Similarly, there were no significant differences between the 
hydrogel alone group and the ACS alone group after 2, 4, 8 and 12 weeks. The 
simvastatin with hydrogel group and the simvastatin with ACS group were significantly 
larger than hydrogel alone group and ACS alone group after 2, 4, 8 and 12 weeks 
(P<0.0001). The control group was significantly smaller than any other groups after 2, 4, 
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In recent years, interest has been shown in the potential effects of statins that 
appear to be different from those well-known on serum cholesterol. Among these, the 
possible effect of statins on bone tissue has received particular attention (McFarlane et 
al. 2002). Mundy et al. (1999) first reported that simvastatin stimulated in vivo bone 
formation in rodents and increased new bone volume in cultures from mouse calvaria. 
Recently, several reports about the positive effect of statins on bone tissue have been 
confirmed both in vitro and in vivo (Maeda et al. 2001; Ohnaka et al. 2001; Montagnani 
et al.2003; Uzzan et al. 2007). 
HMG-CoA reductase is one of the rate-limiting enzymes within the mevalonate 
pathway, through which cholesterol is biosynthesized.  This enzyme is effectively 
inhibited by statins causing a reduction in blood-cholesterol levels. Other products of 
the mevalonate pathway are also important for the prenylation of some kinds of small 
GTPases.  Since small prenylated GTPases are important both for activating 
osteoclasts and inhibiting the synthesis of BMP-2, statins inhibit the prenylation of 
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small GTPases and, as a result, they can increase bone mass systemically (Rogers 
2000).20 
In this study we evaluated the bone regeneration process using two different 
carriers and we compared the bone regenerative capability of these materials 
histologically and immunohistochemically in an animal model.  Regarding use of the 
experimental model, the region of nasal bone of rabbit was comparatively flat and wide, 
so that bone defects with equal size could be made easily. Therefore, it was possible to 
compare the 5 bone defects with similar condition in an rabbit. Furthermore, our 
previous study suggested that 5 mm diameter defects in the rabbit nasal bone were 
adequate size to observe the bone regeneration. It was considered that this animal model 
and the location and dimension of the defect were valid.  Hydrogel and ACS of the 
same size were used as carriers in all groups except in the control group so that the same 
amount of space would be available for bone regeneration. 
Several carriers with suitable characteristics have been developed (Ueki et al. 
2003, Inoda et al. 2004; Alam et al. 2009).  Gelatin hydrogel is a gelatin-based 
hydrogel for the sustained release of the drug. . It was developed on the basis of the 
research results of Tabata et al. (Tabata et al. 1994; Yamamoto et al. 2000; Ozeki et al. 
2001; Yamamoto et al. 2003; Tanigo et al. 2010). ACS was developed as a form of 
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sponge by combining fibrillar atelo-collagen with gelatin, to minimize antigenicity, 
which is cross-linked by heat treatment for biocompatibility (Koide et al. 1993). An 
ideal carrier should not only be resorbed and nonimmunogenic, but it should also 
provide a three-dimensional structure as a scaffold for new bone formation. In this study, 
Hydrogel and ACS were selected as carriers. Hydrogel is used solely for experimental 
studies and cannot be used for human treatment yet. On the other hand, ACS can be 
administered to humans in a clinical setting, because it was approved by ministry of 
health, labour and wealth in Japan. 
Simvastatin is one of many water-insoluble drugs. Therefore, Tanigo et al.  
(2010) reported that simvastatin could be made water soluble by gelatin grafted with 
L-lactic acid oligomer and mixed with gelatin, followed by chemical cross linking to 
obtain gelatin hydrogels incorporating water-soluble simvastatin. However, Mundy et al. 
(1999) first reported that statins stimulated bone formation in rodents in vivo and that 
they increased the volume of new bone in cultures from mouse calvarium.  The 
enhancement of bone formation by statins is associated with an increase in the 
expression of BMP-2 through the activation of the gene promoter. Wong et al. (2005) 
also reported that a pro-drug statin (Zocor®) dissolved in water mixed with absorbable 
collagen sponge can induce BMP expression in surrounding tissues directly, and they 
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found that following implantation of simvastatin, new bone was observed at 5 days 
post-operative.  In this study, there were no findings to suggest the induction of 
inflammation in any of the specimens at 1 week post-operative.  Osteoblasts and 
fibroblasts were clearly observed at 2 weeks post-operative, BMP expression was 
maximum and the formation of new bone was partially observed in both simvastatin 
groups. Significant bone formation was found in the study of Tanigo.et al. (2010), when 
the gelatin hydrogel incorporating statin-micelles was used. Further development of the 
carrier may make the effective bone formation possible. 
Local –dose statin application causes considerable soft tissue inflammation. 
Stein et al. (2005) applied a single dose of 0.1, 0.5, 1.0, 1.5, or 2.2 mg of simvastatin 
and doses ranging from 0.5 mg to 2.2 mg reduced inflammation to a more clinically 
acceptable level without sacrificing bone-growth potential. Lee et al. (2008) confirm 
that 0.5 mg of the statin produced the best bone growth/inflammation ratio. In this study, 
similarly, 2.5 mg/ml simvastatin dissolved in 0.2 ml water was used with two different 
carries  
Osteogenesis induced by osteoblastic cells, is characterized by sequential 
events involving cell proliferation, followed by the expression of markers of osteoblast 
phenotypes and the synthesis, deposition, and mineralization of a collagenous matrix 
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( Bellows et al. 1986; Maniatopoulos et al. 1988). Bone formation depends mainly on 
the number of osteoblastic cells rather than the activity of the osteoblasts (Marie 1995).  
The recruitment of osteoblastic cells plays a crucial role in osteogenesis.  This suggests 
that new bone formation might be seen over a longer post-operative time period than in 
the current study. 
In the present study, most hydrogel and ACS structures containing simvastatin 
could not be seen at 8 weeks post-implantation but could be seen partially in the 
hydrogel alone group and ACS alone group. This suggested there was no significant 
histological difference between the two carriers regarding absorption of the carrier 
structure.  
The change in BMP-2 expression over time showed significant differences when 
the two simvastatin groups were compared with the control group (P < 0.0001).  
Furthermore, when data of the multiple comparison analysis with Scheffe’s F test at 
each period were added, our statistical analysis suggested that BMP-2 was expressed 
more intensely in both groups at 2 weeks post-operative than at the other post-operative 
times. Only the simvastatin with ACS group showed higher values than the control 
group at 1 and 4 weeks postoperative, although there was no significant difference 
between the simvastatin with hydrogel and the control groups.  This result might be 
 21
due to the difference in drug release or the properties of the two carries. At 12 weeks, 
the control group showed a higher value than the other groups. This suggested that 
though slow, there was new bone forming ability even when no material was implanted. 
However, the sample size in each post-operative period was very small and the data 
varied notably such that the significant differences obtained with Scheffe’s F test  
could not be considered as accurate.  Therefore, further examination using a larger 
sample size is required. 
New bone area ratio showed maximum value at 12 weeks postoperative in all 
the groups.  New bone formation in two groups that used simvastatin was recognized 
at an earlier stage than the two different carriers alone. Furthermore, use of these 
carriers could induce new bone formation much more than the control group. This 
proved that the carriers preserved the defect space and act as scaffolds for osteoblast and 
vascular proliferation. However, if progress was observed for more than 24 weeks, bone 
regeneration would have been complete in all the groups.  
Actually, in the current model is impossible to identify whether or not the 
observed osteoblast were “host” osteoblast proliferating from the margins of the defect 
or the product of differentiation process of mesenchymal cells coming from other 
sources as result of the osteoinductive properties of statins. Therefore, number of 
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BMP-2 stained cell was counted at the center region of the defects. However, the fact 
that high number of BMP-2 stained cells was observed at somehow later stages in the 
control groups supported that osteoinductive ability is not necessarily induced by statin. 
This immunohistochemical studies demonstrated that BMP-2 was strongly 
expressed in the connective tissue and periosteum following the implantation of the 
statin in the rabbit nasal bone.  In addition, BMP-2 expression at every postoperative 
week of tissue examination was similar in the sites where statin with hydrogel and statin 
with ACS were used.  We conclude that statin with hydrogel and statin with ACS 
produced similar BMP-2 expression and osteoinductive activity. In short, there was no 
significant difference between hydrogel and ACS, when the statin was used to 
regenerate new bone. In the future, the hydrogel will be more useful carrier in term of 
drug release by improvement fore-mentioned, although it can not be used clinically now. 
It was difficult to compare between the hydrogel and the ACS in the material ptoperties 
and resorption simply. However, when we used the statin with carrier clinically now, the 
ACS can induce similar new bone formation as the carrier.  The results of this study 
can be useful to assert that early introduction of the use of statin in clinical treatment is 
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FIGURE 1.  Intra-operative finding. (A) Bone defect was made at the nasal region. 
(B) Diagram of the superior view of rabbit skull. Showing the sites of 5 surgically 
–created bone defects (1) simvastatin with hydrogel, (2) simvastatin with ACS (3) 
hydrogel alone (4) ACS alone and (5) Control(no material) that were implanted within 
the defects. 
 
FIGURE 2. The coronal section of the nasal region with implanted materials. The 
yellow colored area indicates the area of observation.  
 
FIGURE 3. Histological images of total area after 2 week. (1) simvastatin with 
hydrogel, (2) simvastatin with ACS, (3) hydrogel alone, (4) ACS alone and (5) Control, 
(hematoxylin-eosin staining) 
 
FIGURE 4. Photomicrographs after 1 weeks. (1) simvastatin with hydrogel, 
(2)simvastatin with ACS, (3) hydrogel alone, (4) ACS alone and (5) Control, 
(hematoxylin-eosin staining, original magnification ×400), M：mother bone.  
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FIGURE 5. Photomicrographs after 2 weeks. (1) simvastatin with hydrogel, 
(2)simvastatin with ACS, (3) hydrogel alone, (4) ACS alone and (5) Control, 
(hematoxylin-eosin staining, original magnification ×400), M：mother bone. NB：new 
bone. 
 
FIGURE 6. Photomicrographs after 2 weeks. (1) simvastatin with hydrogel, (2) 
simvastatin with ACS, Red arrows show BMP-2 stained cells. (Immunohistochemical 
staining, original magnification × 100(upper photographs), × 600(lower 
photographs)), M：mother bone. NB：new bone. 
 
FIGURE 7.   Photomicrographs after 4 weeks. (1) simvastatin with hydrogel, (2) 
simvastatin with ACS, (3) hydrogel alone, (4) ACS alone and (5) Control, 
(hematoxylin-eosin staining, original magnification ×400), M：mother bone. NB：new 
bone. 
    
FIGURE 8.    Photomicrographs after 8 weeks. (1) simvastatin with hydrogel, (2) 
simvastatin with ACS, (3) hydrogel alone, (4)ACS alone and (5) Control, 
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(hematoxylin-eosin staining, original magnification ×400), M：mother bone. NB：new 
bone. 
 
FIGURE 9.    Photomicrographs after 12 weeks. (1) simvastatin with hydrogel, (2) 
simvastatin with ACS, (3) hydrogel alone, (4) ACS alone and (5) Control, 
(hematoxylin-eosin staining, original magnification ×400), M：mother bone. NB：new 
bone. 
 
FIGURE 10. The labeling index of BMP-2 positive cells. The time-course of changes 
in all the groups showed significant differences with ANOVA (P<0.0001). SM: 
simvastatin with hydrogel group, ST: simvastatin with ACS group, NM: hydrogel alone 
group, NT: ACS alone group, Control: no implantation group. 
 
FIGURE 11. The ratio of new bone. The time-course of changes in all the groups 
showed significant differences with ANOVA (P<0.0001). SM: simvastatin with 
hydrogel group, ST: simvastatin with ACS group, NM: hydrogel alone group, NT: ACS 
alone group, Control: no implantation group.  
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TABLE 1. The labeling index of BMP-2 positive cells. SM: simvastatin with hydrogel 
group, ST: simvastatin with ACS group, NM: hydrogel alone group, NT: ACS alone 
group, Control: no implantation group. SD shows standard deviation. 
 
TABLE 2. The ratio of new bone. SM: simvastatin with hydrogel group, ST: 
simvastatin with ACS group, NM: hydrogel alone group, NT: ACS alone group, 
Control: no implantation group. SD shows standard deviation. 
 
TABLE 3.  Results (P-value) of comparisons between groups in the labeling index of 
BMP-2 positive cells. SM: simvastatin with hydrogel group, ST: simvastatin with ACS 
group, NM: hydrogel alone group, NT: ACS alone group, Control: no implantation 
group. S shows significant difference at P<0.05. NS shows no significant difference. 
 
TABLE 4. Results (P-value) of comparisons between groups in the ratio of new bone. 
SM: simvastatin with hydrogel group, ST: simvastatin with ACS group, NM: hydrogel 
alone group, NT: ACS alone group, Control: no implantation group. S shows significant 



































































































































1w 2w 4w 8w 12w
ST SM NT NM Control
Fig.11
1w 2w 4w 8w 12w
Mean SD Mean SD Mean SD Mean SD Mean SD
ST 26.3 4.6 157.8 24.8 56.8 5.9 26.5 7.7 10.3 4.1
SM 21.8 10.4 182.0 68.3 46.3 10.6 27.3 13.3 9.3 3.6
NT 21.3 4.0 34.3 10.4 38.3 20.0 16.8 6.2 7.5 4.2
NM 13.5 3.1 44.3 19.3 36.8 11.8 17.8 3.8 8.5 4.5
Control 9.0 3.7 16.5 7.4 22.8 5.0 20.3 8.9 21.0 4.8
Table.1
1w 2w 4w 8w 12w
Mean SD Mean SD Mean SD Mean SD Mean SD
ST 0.0 0.0 14.0 1.1 49.1 0.8 70.1 0.6 98.5 1.7
SM 0.0 0.0 14.8 0.5 49.1 1.0 70.0 0.7 99.0 0.7
NT 0.0 0.0 0.8 1.0 15.7 1.2 49.7 1.5 81.8 2.5
NM 0.0 0.0 0.5 1.0 15.4 0.7 49.4 3.0 83.3 1.7
Control 0.0 0.0 0.0 0.0 0.8 1.0 16.6 1.0 50.8 3.6
Table.2
BMP-2 1w 2w 4w 8w 12w
ST vs SM NS NS NS NS NS
NT vs NM NS NS NS NS NS
ST vs NT NS 0.0029S NS NS NS
SM vs NM NS 0.0011S NS NS NS
ST vs Control 0.015S 0.0008S 0.0199S NS 0.0439S
SM vs Control NS 0.0002S NS NS 0.0248S
NT vs Control NS NS NS NS 0.0089S
NM vs Control NS NS NS NS 0.0160S
Table.3
Bone area ratio 1W 2w 4w 8w 12w
ST vs SM NS NS NS NS
NT vs NM NS NS NS NS
ST vs NT <0.0001S <0.0001S <0.0001S <0.0001S
SM vs NM <0.0001S <0.0001S <0.0001S <0.0001S
ST vs Control <0.0001S <0.0001S <0.0001S <0.0001S
SM vs Control <0.0001S <0.0001S <0.0001S <0.0001S
NT vs Control NS <0.0001S <0.0001S <0.0001S
NM vs Control NS <0.0001S <0.0001S <0.0001S
Table.4
